0001209191-20-054833.txt : 20201014 0001209191-20-054833.hdr.sgml : 20201014 20201014183354 ACCESSION NUMBER: 0001209191-20-054833 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201013 FILED AS OF DATE: 20201014 DATE AS OF CHANGE: 20201014 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Virgin Herbert CENTRAL INDEX KEY: 0001786378 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 201239946 MAIL ADDRESS: STREET 1: C/O VIR BIOTECHNOLOGY, INC. STREET 2: 499 ILLINOIS STREET, SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-13 0 0001706431 Vir Biotechnology, Inc. VIR 0001786378 Virgin Herbert C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 1 0 0 EVP, Research & CSO Common Stock 2020-10-13 4 M 0 5560 1.53 A 29260 D Common Stock 2020-10-13 4 S 0 5560 43.0281 D 23700 D Stock Option (Right to Buy) 1.53 2020-10-13 4 M 0 5560 0.00 D 2028-01-26 Common Stock 5560 454315 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.0249 to $43.0302, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. /s/ Howard Horn, Attorney-in-Fact 2020-10-14